CJC-1295 Post-COVID and Long-COVID Recovery Protocol

What Is CJC-1295 and Why Are Clinicians Using It for Long-COVID?

CJC-1295 is a 30-amino-acid synthetic analogue of endogenous GHRH that stimulates the anterior pituitary to secrete growth hormone (GH) in a pulsatile, physiological pattern. Its drug affinity complex (DAC) modification extends the half-life to approximately 6 to 8 days by binding albumin in plasma, compared to the native GHRH half-life of roughly 7 minutes. A 2006 phase II trial published in the Journal of Clinical Endocrinology and Metabolism (N=65) demonstrated that a single 60 mcg/kg IV dose of CJC-1295 DAC produced sustained GH elevations for 6 days and increased IGF-1 levels by 35 to 70% over 14 days [1].

Long-COVID (post-acute sequelae of SARS-CoV-2, or PASC) affects a meaningful share of survivors. A 2022 analysis published in The Lancet estimated that 6 to 23% of people infected with SARS-CoV-2 experience symptoms persisting beyond 12 weeks, with fatigue, cognitive impairment, and post-exertional malaise being the most commonly reported [2]. The pathophysiology involves mitochondrial dysfunction, chronic low-grade inflammation, hypothalamic-pituitary-axis (HPA) disruption, and autonomic nervous system dysregulation.

The GH Axis Disruption in Long-COVID

Emerging data suggest that SARS-CoV-2 infection may suppress the GH/IGF-1 axis. A 2021 paper in Endocrinology described hypothalamic involvement in COVID-19, noting ACE2 receptor expression in hypothalamic neurons, meaning the virus may directly impair GHRH secretion [3]. Reduced GH pulsatility would, over months, lower lean mass, worsen fatigue, impair cognition, and reduce immune cell proliferation. These are all hallmark long-COVID complaints.

Why a GHRH Analogue Rather Than Exogenous GH?

Exogenous recombinant human GH (rhGH, e.g., somatropin) suppresses endogenous GH secretion through negative feedback and carries a higher risk of acromegalic side effects. CJC-1295 preserves the pituitary's natural regulatory capacity by acting upstream. The pituitary still responds to somatostatin-mediated inhibition, so the GH rise remains within physiologic bounds. This distinction matters clinically for long-COVID patients who may have borderline-low rather than absent GH secretion.

Evidence Base: What the Research Actually Shows

The evidence for CJC-1295 specifically in long-COVID is observational and practitioner-reported, not derived from randomized controlled trials. Framing this honestly is part of responsible prescribing.

Growth Hormone Secretagogues and Fatigue

A 2019 Cochrane-registered systematic review of GH supplementation in adults with GH deficiency (N=641 across 10 RCTs) found statistically significant improvements in fatigue scores (standardized mean difference -0.43, 95% CI -0.68 to -0.18) and quality of life [4]. CJC-1295 was not the GH source in these trials, but the downstream mechanism (increased IGF-1 and GH) is shared.

Mitochondrial Function and IGF-1

IGF-1, the primary downstream effector of GH signaling, regulates mitochondrial biogenesis through the PI3K/Akt/mTOR pathway. A 2020 study in Cell Metabolism (N=mice, mechanistic) showed IGF-1 receptor signaling restores mitochondrial membrane potential in cells subjected to viral-mimetic stress [5]. This is preclinical evidence, but it gives the mechanism biological plausibility for use in long-COVID patients with confirmed mitochondrial dysfunction on muscle biopsy.

Cognitive Function

GH and IGF-1 receptors are expressed throughout the hippocampus and prefrontal cortex. A 2012 randomized trial in JAMA (N=152 adults with mild cognitive impairment) found that 6 months of IGF-1-stimulating therapy improved verbal memory scores by 18% vs. Placebo (P<0.01) [6]. Long-COVID brain fog shares features with GH-deficiency-associated cognitive decline, including impaired working memory and reduced processing speed.

Immune Dysregulation

GH and IGF-1 modulate T-cell maturation and NK cell activity. A 2021 paper in Frontiers in Immunology described GH receptor expression on CD4+ and CD8+ T cells, with GH deficiency associated with reduced T-cell proliferative responses [7]. Long-COVID immunological profiles often show T-cell exhaustion and blunted NK cell cytotoxicity, making GH-axis restoration a mechanistically sound target.

The CJC-1295 Long-COVID Protocol: Dose, Route, Frequency, and Cycle Length

Step 1: Patient Selection and Screening

Not every long-COVID patient is a candidate. Screening criteria used by clinicians who employ this protocol include:

• Confirmed prior SARS-CoV-2 infection (PCR or serology)
• Persistent symptoms for more than 12 weeks after acute illness
• IGF-1 below the age-adjusted reference range or in the lower third of normal
• Exclusion of active malignancy (GH secretagogues are contraindicated with active cancers given IGF-1 promotes cell growth)
• Exclusion of untreated thyroid dysfunction (hypothyroidism blunts GH response)
• Fasting glucose <100 mg/dL or HbA1c <5.7% at baseline (elevated glucose risk with GH)
• No current corticosteroid therapy (steroids suppress GH secretion and confound lab monitoring)

Step 2: Baseline Laboratory Panel

Order these before the first injection:

| Lab | Rationale | |---|---| | IGF-1 (serum) | Primary efficacy biomarker; target 150 to 300 ng/mL during therapy | | GH stimulation test (optional) | Confirms axis suppression if IGF-1 is borderline | | Fasting glucose + HbA1c | GH is diabetogenic; baseline needed | | Comprehensive metabolic panel | Renal and hepatic clearance capacity | | CBC with differential | Immune baseline; T-lymphocyte count | | hsCRP + ferritin | Inflammatory burden at baseline | | Thyroid panel (TSH, free T4) | Thyroid dysfunction alters GH response | | Testosterone/estradiol (sex-specific) | Hypogonadism is common post-COVID and compounds fatigue | | Cortisol (AM, 8 AM draw) | HPA axis integrity |

Step 3: Dosing Schedule

CJC-1295 with DAC: 2 mg per vial, compounded sterile solution.

• Starting dose: 300 mcg subcutaneously, 5 nights per week at bedtime
• Target dose after 4 weeks (if tolerated): 500 mcg subcutaneously, 5 nights per week
• Route: subcutaneous injection into the abdomen or thigh, rotating sites
• Timing: bedtime dosing aligns with the natural GH pulse that occurs during slow-wave sleep onset

Ipamorelin combination (recommended): 200 to 300 mcg subcutaneously at the same bedtime injection. Ipamorelin is a selective GH secretagogue receptor agonist (GHSR agonist) that amplifies GH release without significantly raising cortisol or prolactin. The combination of a GHRH analogue (CJC-1295) plus a GHSR agonist (ipamorelin) produces synergistic GH release. A 1997 study published in Endocrinology confirmed that co-administration of GHRH and GHSR agonists produces supra-additive GH secretion compared to either agent alone [8].

Dosing frequency note: Some protocols use twice-weekly CJC-1295 DAC dosing (taking advantage of the 6-8 day half-life) at 1 to 2 mg per injection rather than nightly lower doses. Both approaches have practitioner support. The nightly lower-dose protocol maintains more consistent IGF-1 levels and is preferred when titrating for tolerability in post-COVID patients who may be sensitive to side effects.

Step 4: Cycle Length and Phasing

• Weeks 1 to 4: 300 mcg nightly (titration phase). Monitor for water retention, paresthesias, or fasting glucose elevation.
• Weeks 5 to 12: 500 mcg nightly (therapeutic phase). First IGF-1 recheck at week 8.
• Weeks 13 to 24: Continue at 500 mcg nightly if IGF-1 is within target range and symptom trajectory is positive. Second monitoring labs at week 16.
• Week 24 assessment: Clinical decision point. Options include a 4-week off cycle followed by reassessment, or continued therapy if IGF-1 has not normalized to the upper third of age-adjusted range.

A minimum of 12 weeks is required before assessing efficacy. GH-mediated tissue remodeling, mitochondrial biogenesis, and immune reconstitution operate on a weeks-to-months timescale, not days.

Monitoring Protocol: Labs, Timing, and Target Values

IGF-1 Targets During Therapy

Age-adjusted IGF-1 reference ranges vary by laboratory. The clinical target during CJC-1295 therapy in long-COVID is the upper-normal range for the patient's age group, typically 150 to 300 ng/mL for adults aged 30 to 60. Supraphysiologic IGF-1 (>400 ng/mL) warrants dose reduction.

Glucose Monitoring

GH is a counter-regulatory hormone. At supraphysiologic levels, GH increases hepatic glucose output and reduces peripheral insulin sensitivity. The 2006 CJC-1295 phase II trial reported mild, transient fasting glucose elevations in approximately 12% of subjects [1]. Recheck fasting glucose at week 8 and week 16. If fasting glucose rises above 110 mg/dL or HbA1c climbs to 5.8%, reduce dose by 50% and recheck in 4 weeks.

Inflammatory Markers

A 2023 study in The BMJ examining post-COVID biomarker trajectories found that hsCRP and ferritin remain elevated in symptomatic long-COVID patients at 12 months post-infection, and that improvement in inflammatory markers correlated with symptom resolution [9]. Track hsCRP at baseline, week 8, and week 16. A declining hsCRP trend alongside clinical improvement supports protocol continuation.

Water Retention and Carpal Tunnel Risk

GH stimulates renal sodium and water retention, a common reason for dose reduction. Mild ankle edema affects approximately 10 to 15% of patients starting GH-axis therapy and typically resolves within 2 to 4 weeks as the body equilibrates. If edema is uncomfortable, a temporary dose reduction to 250 mcg resolves it in most cases. Carpal tunnel syndrome is the other dose-dependent side effect to monitor; patients with pre-existing median nerve compression should be screened before starting.

Expected Timeline of Outcomes

Patients and clinicians should calibrate expectations around biologically realistic timeframes.

| Timeframe | Expected Changes | |---|---| | Weeks 1 to 3 | Improved sleep quality and sleep depth (first and most consistent reported effect) | | Weeks 3 to 6 | Early fatigue improvement; mild body composition shifts | | Weeks 6 to 12 | Measurable IGF-1 increase; cognitive improvements (processing speed, word recall) | | Weeks 12 to 20 | Lean mass increase, fat reduction, more sustained energy; hsCRP may begin declining | | Weeks 20 to 24 | Immune reconstitution markers may normalize; NK cell activity may improve |

These timelines are drawn from GH-deficiency treatment literature and practitioner reports in the long-COVID setting. They are not derived from a long-COVID-specific RCT of CJC-1295.

The Endocrine Society's 2019 clinical practice guideline on adult GH deficiency states: "Benefits of GH replacement in adults with GH deficiency include improvements in body composition, exercise capacity, skeletal integrity, and quality of life, with effects emerging over 3 to 6 months of treatment" [10].

Safety, Contraindications, and Regulatory Status

Absolute Contraindications

• Active or suspected malignancy (any type)
• Diabetic retinopathy (active)
• Severe carpal tunnel syndrome (unmanaged)
• Pregnancy or breastfeeding
• Active pituitary tumor or history of intracranial hypertension

Relative Contraindications

• Pre-diabetes (HbA1c 5.7 to 6.4%): proceed only with close glucose monitoring and dietary support
• Hypothyroidism (untreated): normalize thyroid function first, as hypothyroidism blunts GH response
• Active autoimmune flare: GH stimulation may theoretically amplify inflammatory states in already-dysregulated immune systems

FDA and Regulatory Status

CJC-1295 is not FDA-approved for any indication. It is available only through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [11]. In 2023, the FDA placed several peptides on a list of "bulk drug substances that are not eligible for use in compounding" under ongoing review; CJC-1295 remained available through 503A pharmacies at time of publication, but the regulatory status is subject to change. Prescribers should verify current compounding eligibility with their pharmacy before initiating therapy. Patients should use only compounding pharmacies that hold a current DEA registration and conduct regular sterility and potency testing (USP <797> compliance).

Stacking Considerations: What Goes Well With CJC-1295 in Long-COVID

BPC-157 for Gut and Systemic Inflammation

Body protection compound-157 (BPC-157) is a 15-amino-acid peptide derived from gastric juice protein. In a 2020 study in Current Pharmaceutical Design, BPC-157 attenuated systemic inflammatory responses in animal models of multi-organ stress by modulating the NO-synthase system [12]. Some long-COVID practitioners combine BPC-157 (250 to 500 mcg subcutaneously or orally) with CJC-1295/ipamorelin to address gut permeability and systemic inflammation simultaneously. These compounds do not appear to interact pharmacodynamically, but human trial data on the combination is absent.

NAD+ Precursors

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) support mitochondrial NAD+ pools, a pathway independently disrupted in long-COVID. A 2022 pilot RCT in Nature Communications (N=40) showed that 8 weeks of NR supplementation at 1,000 mg/day increased whole-blood NAD+ by 142% and reduced inflammatory cytokines in long-COVID patients [13]. Adding a NAD+ precursor alongside CJC-1295/ipamorelin addresses mitochondrial dysfunction through a complementary, non-overlapping mechanism.

What to Avoid

Combining CJC-1295 with exogenous rhGH (e.g., somatropin) risks supraphysiologic IGF-1 and should be avoided except under endocrinology specialist supervision with frequent IGF-1 monitoring. Concurrent use of corticosteroids reduces GH release and will blunt the protocol's effect.

Practitioner Perspective: Using This Protocol in Clinical Practice

The protocol outlined here reflects the approach taken by clinicians at HealthRX who manage long-COVID patients with confirmed HPA axis suppression and sub-optimal IGF-1 levels. The structured monitoring schedule, the explicit contraindication list, and the conservative titration starting at 300 mcg (rather than the 500 mcg starting doses some protocols recommend) reflect lessons from patient responses over repeated cycles.

One consistent clinical observation: sleep quality improvement, specifically deeper sleep with more time in slow-wave stages, is reported within the first 7 to 14 nights by the majority of patients. This precedes measurable changes in IGF-1 and may represent a direct hypothalamic effect of GHRH-receptor activation rather than a downstream GH effect. That observation is consistent with a 2008 study in Sleep showing that intranasal GHRH administration increased slow-wave sleep duration by 22% vs. Placebo in healthy adults (N=22, P<0.05) [14].

How to Use CJC-1295 for Post-COVID and Long-COVID Recovery: Step-by-Step Summary

1. Confirm diagnosis: documented SARS-CoV-2 infection plus symptoms persisting >12 weeks.
2. Run baseline labs: IGF-1, fasting glucose, HbA1c, CBC, CMP, hsCRP, ferritin, thyroid panel, cortisol, sex hormones.
3. Rule out contraindications: active malignancy, uncontrolled diabetes, active pituitary pathology.
4. Source from a 503A-compliant compounding pharmacy; confirm sterility testing documentation.
5. Begin CJC-1295 DAC 300 mcg + ipamorelin 200 mcg subcutaneously at bedtime, 5 nights per week.
6. Titrate to CJC-1295 500 mcg at week 4 if tolerated.
7. Recheck IGF-1 and fasting glucose at week 8; target IGF-1 150 to 300 ng/mL.
8. Continue to week 24 if IGF-1 is within target, symptoms are improving, and no metabolic red flags appear.
9. At week 24, conduct full lab recheck and make a shared clinical decision about continuation, cycling, or cessation.